Abstract
The emergence of multidrug-resistant tuberculosis (MDR-TB) has become a serious challenge for China as well as for others in the world. Incorrect usage of anti-tuberculosis (anti-TB) drugs and the lack of patient treatment compliance are identified as two main factors contributing to the rising number of MDR-TB cases in China. The national government, therefore, has instituted a series of measures to control MDR-TB, which includes carrying out the drug resistance surveillance, improving TB treatment management information systems, issuing new directory national and regional public health policies, implementing pilot programmatic management of MDR-TB, and carrying out related medical and clinical research. In the future, MDR-TB control will be one of the top priorities of TB prevention and control in China.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Center for Disease Control and Prevention & Ministry of Health of the People’s Republic of China. (2008). The national tuberculosis control for public knowledge and behavior findings report. Beijing: Peking Union Medical College Press.
Chen, M. (2009). Global tuberculosis control and treatment of patients with multi drug resistance/extensively drug-resistant TB high-burden countries ministerial conference held in Beijing. Chinese Journal of Anti-tuberculosis, 31(5), 320.
Chinese Antituberculosis Association. (2010). Guideline for drug resistant tuberculosis chemotherapy. Chinese Journal of Tuberculosis and Respiratory Diseases, 33(7), 485–497.
Chinese Center for Disease Control and Prevention, Chinese Antituberculosis Association, & Chinese Medical Association. (2008). Anti tuberculosis drug user manual. Beijing: Peking Union Medical College Press.
Guo, Y., Zhou, Y., Wang, C., Zhu, L., Wang, S., Li, Q., et al. (2009). Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system. The International Journal of Tuberculosis and Lung Disease, 13(7), 914–920.
He, G. X., van den Hof, S., van der Werf, M. J., Guo, H., Hu, Y. L., Fan, J. H., et al. (2011). Inappropriate tuberculosis treatment regimens in Chinese tuberculosis hospitals. Clinical Infectious Diseases, 52(7), e153–e156.
Huang, F., Du, X., Chen, W., Cheng, S., & Wang, L. (2011). Introduction of Tuberculosis Information Management System in China. China Digital Medicine, 6(10), 97–99.
Mi, F. L., Wang, L. X., Li, L., Li, R. Z., Zhang, H., Jiang, S. W., et al. (2011). Effect analysis of China Global Fund Multi-drug Resistant Tuberculosis Project. Tuberculosis and Thoracic Tumor, 1, 1–4.
Ministry of Health of the People’s Republic of China. (2010). National tuberculosis drug resistance survey report (2007-2008). Beijing: People’s Health & Hygiene Press.
Ministry of Health of the People’s Republic of China. (2011). The national tuberculosis control program (2001-2010) 2006-2010 implementation plan. Retrieved April 24, 2015, from http://www.chinacdc.cn/n272442/n272530/n272742/11164.html
Tu, D. H. (2006). Establishing DOTS-Plus strategy for control of multi-drug resistant tuberculosis. Chinese Journal of Tuberculosis and Respiratory Diseases, 29(8), 507–508.
Wang, X. (2006). The prevention of MDR-TB. Chinese Journal of Tuberculosis and Respiratory Diseases, 29(8), 511–513.
Wang, L. X., Cheng, S. M., He, G. X., & Chen, M. T. (2010). Handbook of tuberculosis infection prevention and control in China. Beijing: Peking Union Medical College Press.
Wang, L., Yue, S., Qian, Y., Duanmu, H., & Yang, H. (2002). Socio-economic study on pulmonary tuberculosis patients. Chinese Journal of Antituberculosis, 24, 130–133.
WHO. (2006). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization.
WHO. (2007). Global tuberculosis control: WHO report 2007. Geneva: World Health Organization.
WHO. (2008a). Anti-tuberculosis drug resistance in the world. Fourth global report. Geneva: World Health Organization.
WHO. (2008b). Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. Geneva: World Health Organization.
WHO. (2009). A ministerial meeting of high M/XDR-TB burden countries: Meeting report. Geneva: World Health Organization. WHO/HTM/TB/2009.415. Retrieved April 18, 2011, from http://whqlibdoc.who.int/hq/2009/WHO_HTM_TB_2009.415_eng.pdf?ua=1Accessed
WHO. (2010a). Global tuberculosis control: WHO report 2010. Geneva: World Health Organization.
WHO. (2010b). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization.
Xiao, D. (2011). The National Tuberculosis control program (2001 – 2010) assessment report. Beijing: Military Medical Science Press.
Yang, X. Y., Li, Y. P., Mei, Y. W., Yu, Y., Xiao, J., Luo, J., et al. (2010). Time and spatial distribution of multidrug-resistant tuberculosis among Chinese people, 1981–2006: A systematic review. International Journal of Infectious Diseases, 14(10), 828–837.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this chapter
Cite this chapter
Zhang, H., Chen, M., Li, R., Xu, C. (2017). The MDR-TB Epidemic in China: The Changing Landscape, Cause Analysis, Government Response, Current Status, and Future Aspects. In: Lu, Y., Wang, L., Duanmu, H., Chanyasulkit, C., Strong, A., Zhang, H. (eds) Handbook of Global Tuberculosis Control. Springer, Boston, MA. https://doi.org/10.1007/978-1-4939-6667-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6667-7_11
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4939-6665-3
Online ISBN: 978-1-4939-6667-7
eBook Packages: MedicineMedicine (R0)